Construction of In Situ Personalized Cancer Vaccines by Bioorthogonal Catalytic Microneedles for Augmented Melanoma Immunotherapy
Small · 2025
DOI: 10.1002/smll.202500015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Qian-He Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Functional Materials Chemistry, Key Laboratory for Advanced Materials, School of Chemistry and Molecular Engineering, East…. Hauptthemen laut MEDLINE: Immunotherapy, Cancer Vaccines, Melanoma, Needles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Macao Science and Technology Development Fund, Fundo para o Desenvolvimento das Ciências e da Tecnologia.
Abstract (Originalsprache)
In situ personalized tumor vaccines are produced directly at the primary tumor site by killing cancer cells and stimulating immune cells, they are effective against individuals and bypass the complexity and high cost of in vitro vaccine production. However, their clinical application is hindered by insufficient efficiency in inducing immunogenic cancer cell death (ICD) and systemic inflammation caused by immune adjuvants. Here, personalized cancer vaccines are constructed in situ for melanoma immunotherapy based on bioorthogonal catalytic microneedles, which enable the catalytic release of prodrugs at tumor sites and mediate strong ICD and an enhanced tumor immune response while avoiding systemic immune storms and toxic side effects. By incorporating TiO 2 nanosheets supported Pd into swellable microneedles, the bioorthogonal microneedles are constructed to catalyze the depropargylation reaction of doxorubicin (DOX) prodrug and imiquimod (IMQ) prodrug in situ. The activated DOX at subcutaneous tumor sites induced strong ICD and released tumor‐associated antigens. Concurrently, the activated IMQ acts as a Toll‐like receptor (TLR7) agonist, enhancing the anti‐tumor immune response. In vivo experiments demonstrate that this immunotherapy achieves ≈97% inhibition of primary tumors and effectively inhibits untreated distant tumors (≈94% inhibition) and lung metastasis (≈92% inhibition).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Key Laboratory of Functional Materials Chemistry, Key Laboratory for Advanced Materials, School of Chemistry and Molecular Engineering, East China University of Science & Technology, Shanghai, 200237, China.
- Centre for Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao, 999078, China.
- State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
ORCID-Profile: Pei-Nian Liu
Förderung
- National Natural Science Foundation of China
- Macao Science and Technology Development Fund
- Fundo para o Desenvolvimento das Ciências e da Tecnologia
Zitieren
APA
Xu, Q. H., Yin, X. Y., Chen, Z. Q., Huang, E. K., Yao, X., Li, X., & Liu, P. N. (2025). Construction of In Situ Personalized Cancer Vaccines by Bioorthogonal Catalytic Microneedles for Augmented Melanoma Immunotherapy. Small. https://doi.org/10.1002/smll.202500015
Vancouver
Xu QH, Yin XY, Chen ZQ, Huang EK, Yao X, Li X, et al. Construction of In Situ Personalized Cancer Vaccines by Bioorthogonal Catalytic Microneedles for Augmented Melanoma Immunotherapy. Small. 2025. doi:10.1002/smll.202500015
BibTeX
@article{Xu2025,
author = {Xu, Qian-He and Yin, Xiu-Yuan and Chen, Zhen-Qiang and Huang, En-Kui and Yao, Xiaojun and Li, Xingguang and Liu, Pei-Nian},
title = {Construction of In Situ Personalized Cancer Vaccines by Bioorthogonal Catalytic Microneedles for Augmented Melanoma Immunotherapy},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202500015}
}
EUVIMED